ArticleNature immunology2021
Metabolic reprogramming of terminally exhausted CD8
Open access · greenAbstract read
In one paragraph
Article in Nature immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 271 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
271citing papers in PubMed, 1 pooled it
23.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
271 citing papers in PubMed, 1 synthesis or guideline pooled it, 398 citations in OpenAlex.
- Mapping the clinical landscape of multifunctional CAR T cells: Targets, trends, and synergies.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Pooled it
- Sequential combination of anti-PD-1 antibody and PEG-IFNα in chronic hepatitis B patients: correlates of HBsAg loss with enhanced T-cell responses.Emerging microbes & infections · 2026Trial
- Engineering "off-the-shelf" TCR-T cells: A transient mRNA platform for balanced alloreactivity and functionality.Molecular therapy. Oncology · 2026Article
- Inhibitory receptor profiles for joint prediction of benefit and toxicity in immune checkpoint blockade.iScience · 2026Review
- Review
- Overcoming T cell exhaustion and senescence in CAR T cell therapy for solid tumors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Ex vivo pretreatment with venetoclax boosts antileukemic efficacy of therapeutic γδ T cells in AML models.The Journal of clinical investigation · 2026Article
- Tumor-targeted IL-10 synergizes with IL-2 to enhance antitumor immunity while minimizing immune-related adverse events.Nature communications · 2026Article
- Cytokine fusion proteins for solid tumor therapy: mechanistic insights and clinical advances.Journal of hematology & oncology · 2026Review
- Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies.Experimental hematology & oncology · 2026Review
- Metabolic convergence of diabetes and prostate cancer: from dysglycemia to tumor microenvironment reprogramming.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Review
- Oral nano-delivery of a gut microbial metabolite enhances T cell stemness for cancer immunotherapy.Nature nanotechnology · 2026Article
- Cell-based cancer immunotherapy: milestones, mechanistic insights, and emerging therapeutic directions.Acta pharmacologica Sinica · 2026Review
- Adoptive cell therapy in lung cancer: progress, challenges, and prospects.Chinese medical journal pulmonary and critical care medicine · 2026Review
- Targeting PKM2 Enhances the Anti-Tumor Function of CD8International journal of molecular sciences · 2026Article
- Nicotinamide riboside enhances adoptive T cell therapy by promoting memory differentiation and metabolic fitness.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Mitochondrial Carrier SLC25A13 Drives Ferroptosis Resistance and Immune Evasion via a STAT3-IFI6 Circuit in Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Metabolic rewiring of the dendritic cell-T cell axis: tumour-derived barriers and therapeutic opportunities.Experimental & molecular medicine · 2026Review
- IL-10 secretion by CD8 T cells orchestrates early NK cell recruitment and antitumor immunity after anti-VEGFR-2/PD-1 therapy.Journal for immunotherapy of cancer · 2026Article
- Article
211 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 8 institutions in 4 countries.
Yugang Guo *Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.ORCID 0000-0003-4499-8274
Yu-Qing Xie *Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.ORCID 0000-0003-3996-2234
Min GaoInstitute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.ORCID 0000-0003-2106-0267
Yang ZhaoInstitute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Fabien FrancoDepartment of Oncology, University of Lausanne, Epalinges, Switzerland.
Mathias WenesDepartment of Oncology, University of Lausanne, Epalinges, Switzerland.
Imran SiddiquiDepartment of Oncology, University of Lausanne, Epalinges, Switzerland.
Alessio BevilacquaDepartment of Oncology, University of Lausanne, Epalinges, Switzerland.ORCID 0000-0001-7009-4362
Haiping WangDepartment of Oncology, University of Lausanne, Epalinges, Switzerland.
Hanshuo YangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, China.
Bing FengInstitute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Xin XieCenter for Genomics and Systems Biology, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates.ORCID 0000-0002-6784-4860
Catherine M SabatelDepartment of Oncology, University of Lausanne, Epalinges, Switzerland.
Benjamin TschumiDepartment of Oncology, University of Lausanne, Epalinges, Switzerland.
Amphun ChaiboonchoeSiriraj Center of Research Excellence for Systems Pharmacology, Department of Pharmacology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.ORCID 0000-0002-0009-0806
Yuxi WangDepartment of Respiratory and Critical Care Medicine, West China Medical School/West China Hospital, Sichuan University, Chengdu, China.
Weimin LiDepartment of Respiratory and Critical Care Medicine, West China Medical School/West China Hospital, Sichuan University, Chengdu, China.
Weihua XiaoDepartment of Oncology of the First Affiliated Hospital, Division of Life Sciences and Medicine, The CAS Key Laboratory of Innate Immunity and Chronic Disease, Hefei National Laboratory for Physical Sciences at Microscale, University of Science and Technology of China, Hefei, China.
Werner HeldDepartment of Oncology, University of Lausanne, Epalinges, Switzerland.ORCID 0000-0003-3292-1536
Pedro RomeroDepartment of Oncology, University of Lausanne, Epalinges, Switzerland.ORCID 0000-0002-9688-2882
Ping-Chih HoDepartment of Oncology, University of Lausanne, Epalinges, Switzerland. ping-chih.ho@unil.ch.ORCID 0000-0003-3078-3774
Li TangInstitute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. li.tang@epfl.ch.ORCID 0000-0002-6393-982X
École Polytechnique Fédérale de Lausanne · CHUniversity of Lausanne · CHLudwig Cancer Research · CHWest China Medical Center of Sichuan University · CNNew York University Abu Dhabi · AESichuan University · CNSiriraj Hospital · THUniversity of Science and Technology of China · CN
Funding
Swiss National Science Foundation 173243
Abstract
T cell exhaustion presents one of the major hurdles to cancer immunotherapy. Among exhausted CD8
Indexed as
AnimalsAnion Transport ProteinsCell Line, TumorCombined Modality TherapyDisease Models, AnimalDrug SynergismFemaleHalf-LifeHEK293 CellsHumansImmune Checkpoint InhibitorsImmunoglobulin Fc FragmentsImmunotherapy, AdoptiveInterleukin-10MiceMice, TransgenicAnion Transport ProteinsIL10 protein, humanImmune Checkpoint InhibitorsImmunoglobulin Fc FragmentsInterleukin-10Mitochondrial Membrane Transport ProteinsMonocarboxylic Acid TransportersMPC1 pyruvate carrier protein, mouseReceptors, Chimeric AntigenReceptors, Interleukin-10Recombinant Fusion Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.